军事知识服务平台
阿达木单克隆抗体治疗克罗恩病的诱导期血药谷浓度与短期内镜应答的相关性分析
Correlation between serum adalimumab trough concentration during the induction phase and short-term endoscopic response in Crohn's disease
摘要 目的:分析阿达木单克隆抗体(ADA)治疗克罗恩病(CD)的12周血药谷浓度与(32±8)周内镜应答的关系。方法:采用队列研究方法。回顾性纳入2019年6月至2023年12月在南京大学医学院附属鼓楼医院启动ADA治疗的CD患者,收集一般资料、内镜评分、实验室检查、12周治疗前ADA血药谷浓度,以及随访过程中的内镜和临床应答情况。根据(32±8)周内镜复查情况分为内镜应答组和内镜无应答组,比较两组12周ADA血药谷浓度和其他一般资料,以及与(32±8)周时内镜应答相关因素。结果:共纳入34例CD患者,男性23例(67.6%),女性11例(32.4%)。内镜应答组共18例(52.9%),内镜无应答组16例(47.1%)。内镜应答组的12周ADA血药谷浓度显著高于内镜无应答组[(12.5±7.8)μg/mL比(6.3±3.4)μg/mL, P=0.005]。内镜应答组的12周ADA有效谷浓度是8.75 μg/mL,AUC值为0.774(95% CI:0.609~0.939, P=0.006),敏感度为72.2%,特异度75.0%。多变量Logistic回归分析得出12周ADA谷浓度≥8.75 μg/mL( OR=0.132,95% CI:0.028~0.621, P=0.010)与内镜应答显著相关。ADA诱导治疗12周后的临床应答率为91.1%(31/34),后续发生继发失应答率为51.6%(16/31)。总体不良反应发生率为20.6%(7/34)。 结论:ADA治疗12周后的ADA血药谷浓度与(32±8)周内镜应答密切相关,总体安全性良好。
Abstract:
Objective:To analyze the correlation between the 12-week serum adalimumab(ADA)trough concentration and endoscopic response at(32±8)weeks in patients with Crohn's disease(CD)treated with ADA.Methods:A retrospective cohort study was conducted. Patients with CD who initiated ADA treatment at Drum Tower Hospital Affiliated to Nanjing University Medical School from June 2019 to December 2023 were retrospectively enrolled. Baseline characteristics,endoscopic scores,laboratory test results,serum ADA trough concentrations before the week 12 dose,and endoscopic and clinical responses during follow-up were collected. Patients were stratified into the endoscopic response group and endoscopic non-response group according to endoscopic re-examination results at(32±8)weeks. The 12-week serum ADA trough concentrations and baseline data were compared between the two groups,and factors associated with endoscopic response at(32±8)weeks were analyzed.Results:A total of 34 patients with CD were included,consisting of 23 men(67.6%)and 11 women(32.4%). Eighteen patients(52.9%)achieved endoscopic response and 16 patients(47.1%)had no endoscopic response. The 12-week serum ADA trough concentration was significantly higher in the endoscopic response group than in the non-response group[(12.5±7.8)μg/mL vs.(6.3±3.4)μg/mL, P=0.005]. The optimal 12-week threshold of serum ADA trough concentration for predicting endoscopic response at(32±8)weeks was 8.75 μg/mL,with an AUC of 0.774(95% CI:0.609~0.939, P=0.006),a sensitivity of 72.2%,and a specificity of 75.0%. Multivariate logistic regression analysis demonstrated that a 12-week serum ADA trough concentration ≥8.75 μg/mL( OR=0.132,95% CI:0.028~0.621, P=0.010)was significantly associated with endoscopic response. The clinical response rate after 12 weeks of ADA induction therapy was 91.1%(31/34),and the rate of subsequent secondary loss of response was 51.6%(16/31). The overall incidence of adverse reactions was 20.6%(7/34). Conclusion:The serum ADA trough concentration at week 12 is closely associated with endoscopic response at(32±8)weeks in patients with CD receiving ADA treatment,with a favorable overall safety profile.